Goodwin Procter and Baker McKenzie advised Trillium Therapeutics on the deal, while Ropes & Gray LLP and Norton Rose Fulbright Canada represented Pfizer. Trillium Therapeutics (NASDAQ/TSX:...
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here